| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | David E Soper | |
| Oluwatosin Jaiyeoba | |||
| Gweneth Lazenby | |||
| P2860 | cites work | Persistence of Mycoplasma genitalium following azithromycin therapy | Q33382111 |
| Mycoplasma genitalium -- an up-date | Q34115532 | ||
| Improvement in the clinical cure rate of outpatient management of pelvic inflammatory disease following a change in therapy | Q34558039 | ||
| Failure of cefoxitin and doxycycline to eradicate endometrial Mycoplasma genitalium and the consequence for clinical cure of pelvic inflammatory disease. | Q34591252 | ||
| Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates | Q35114374 | ||
| Detection of Mycoplasma genitalium in women with laparoscopically diagnosed acute salpingitis | Q35531997 | ||
| Azithromycin failure in Mycoplasma genitalium urethritis | Q35792616 | ||
| Epidemiology, pathogenesis and treatment of pelvic inflammatory disease. | Q36441494 | ||
| Antibiotic therapy for acute pelvic inflammatory disease: the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines | Q36753465 | ||
| Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial | Q36928663 | ||
| Clinical presentation of Mycoplasma genitalium Infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease | Q37119362 | ||
| Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study | Q37852511 | ||
| Comparison of acute and subclinical pelvic inflammatory disease. | Q37864558 | ||
| Significant reduction in inflammatory response in the macaque model of chlamydial pelvic inflammatory disease with azithromycin treatment | Q37864682 | ||
| The antimicrobial treatment of subacute endometritis: a proof of concept study | Q37867684 | ||
| Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease | Q37869865 | ||
| Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease | Q37871257 | ||
| A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource-poor setting | Q37871971 | ||
| Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin | Q37897569 | ||
| Chilamydia trachomatis infection in patients with acute salpingitis | Q37911703 | ||
| Polymicrobial etiology of acute pelvic inflammatory disease | Q37912486 | ||
| Current trends in the diagnosis and treatment of tuboovarian abscess | Q40818731 | ||
| Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections | Q41676368 | ||
| Antibiotic treatment of tuboovarian abscess: comparison of broad-spectrum beta-lactam agents versus clindamycin-containing regimens | Q41922847 | ||
| A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men. | Q42170059 | ||
| Penetration and accumulation of moxifloxacin in uterine tissue | Q42656723 | ||
| A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease | Q43264842 | ||
| Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial | Q43816502 | ||
| Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial | Q43996846 | ||
| Antimicrobial resistance associated with the treatment of bacterial vaginosis. | Q45126910 | ||
| A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. | Q54480935 | ||
| P433 | issue | 1 | |
| P921 | main subject | pelvic inflammatory diseases | Q558070 |
| P304 | page(s) | 61-70 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Recommendations and rationale for the treatment of pelvic inflammatory disease | |
| P478 | volume | 9 |
| Q95851757 | A Need for Standardization of the Diagnosis and Treatment of Pelvic Inflammatory Disease: Pilot Study in an Outpatient Clinic in Quito, Ecuador |
| Q98169962 | Clinical comparison of five anti-chlamydial antibiotics in koalas (Phascolarctos cinereus) |
| Q92434599 | Clinical value of early laparoscopic therapy in the management of tubo-ovarian or pelvic abscess |
| Q31136103 | Effective photodynamic therapy against microbial populations in human deep tissue abscess aspirates |
| Q38634760 | Human parasitic protozoan infection to infertility: a systematic review |
| Q26999090 | Individualized medicine and the microbiome in reproductive tract |
| Q26740424 | Mollicutes/HIV Coinfection and the Development of AIDS: Still Far from a Definitive Response |
| Q34269050 | Recent perspectives in the diagnosis and evidence-based treatment of Mycoplasma genitalium |
| Q41577929 | Risk factors for adverse clinical outcomes in patients with tubo-ovarian abscess |
| Q36092095 | Secretory leukocyte protease inhibitor binds to Neisseria gonorrhoeae outer membrane opacity protein and is bactericidal |
| Q34310337 | Surveillance of antibiotic consumption using the "focus of infection" approach in 2 hospitals in Ujjain, India |
Search more.